Escolar Documentos
Profissional Documentos
Cultura Documentos
Hi Guest User,
(Note that this account is the default account and that any data saved will be visible to all
users. Please register for a personal account if you need to save any data for personal use.)
Overview >>
Gastric adenocarcinoma is the second leading cause of cancer death worldwide. It is
particularly common in Asia and especially in China and Japan. In Singapore it is the
fourth most common cancer in males who have a 1:50 lifetime risk of developing gastric
cancer. Gastric cancer traditionally carries a poor prognosis with 79% of tumors
diagnosed at stage IV and five year survival less than 5%. Advanced gastric cancer is
generally refractory to chemotherapy, which leads to poor prognosis. It has been shown
that if it is diagnosed at an early stage, it is a curable disease. Therefore it is most
important to be able to identify clinically useful early markers that can detect gastric
cancer at an early stage.
Aims
This knowledgebase integrates available information from various sources to help
find out the genes responsible for the formation of gastric cancers
activation of oncogenes
p53
(Mutated p53 isoforms can generate an
autoimmune response. Serum anti-p53
antibodies can serve as a diagnostic and
prognostic marker in gastric cancer
patients.
Cdks
(Regulators cyclin-dependent kinases
(CDKs 1, 2, 4 and 6) and their inhibitors
(p15, p16, p21waf1/cip1 and p27kip1) are also
expressed in gastric cancer tissues.
Src
VEGF receptor (KDR)
Hek5 (Erk)
Abl, nerve growth factor receptor
(TrkA)
Stem cell factor receptor (c-Kit)
References >>
Wobbes, T. et al. (1992) Evaluation of seven tumor markers (CA 50, CA 19-9,
CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue
polypeptide antigen) in the pretreatment sera of patients with gastric
carcinoma. Cancer 69, 2036-2041, PubMed
Tocchi, A. et al. (1998) The role of serum and gastric juice levels of
carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric
cancer. J Cancer Res Clin Oncol 124, 450-455, PubMed
Lin, J.T. et al. (1993) Serum levels of pepsinogen I and gastrin in gastric
carcinoma: the influence of Helicobacter pylori infection and tumor
characteristics. Hepatogastroenterology 40, 600-603, PubMed
Brien, T.P. et al. (1998) Prognostic factors in gastric cancer. Mod Pathol 11,
870-877, PubMed
Wu, M.S. et al. (1998) Overexpression of mutant p53 and c-erbB-2 proteins
and mutations of the p15 and p16 genes in human gastric carcinoma: with
respect to histological subtypes and stages. J Gastroenterol Hepatol 13, 305310, PubMed
Myung, N. et al. (2000) Loss of p16 and p27 is associated with progression of
human gastric cancer. Cancer Lett 153, 129-136, PubMed
Tahara, E. (1995) Molecular biology of gastric cancer. World J Surg 19, 484488; discussion 489-490, PubMed
Taniguchi, K. et al. (1998) The relation between the growth patterns of gastric
carcinoma and the expression of hepatocyte growth factor receptor (c-met),
autocrine motility factor receptor, and urokinase-type plasminogen activator
receptor. Cancer 82, 2112-2122, PubMed
Wu, C.W. et al. (1998) Hepatocyte growth factor and Met/HGF receptors in
patients with gastric adenocarcinoma. Oncol Rep 5, 817-822, PubMed
Yonemura, Y. et al. (1989) Epidermal growth factor receptor status and Sphase fractions in gastric carcinoma. Oncology 46, 158-161, PubMed